非小细胞肺癌患者癌组织RAR-β基因甲基化的检测及其临床意义

The detection and clinical implication of methylation of RAR-β gene in patients with non-small cell lung cancer

目的研究非小细胞肺癌患者癌组织RAR-β基因甲基化及其临床意义。方法选择80例非小细胞肺癌患者,用甲基化特异性PCR（MSP）检测肺癌组织和癌旁正常组织RAR-β基因甲基化。结果肺癌组织RAR-β基因甲基化率（57.5%）高于癌旁组织甲基化率（17.5%）,差异有统计学意义（P〈0.01）;临床分期0-Ⅰ期与Ⅱ-Ⅲ期相比、中央型与周围型相比,肺癌组织RAR-β基因甲基化检出率差异无统计学意义（P〉0.05）;不同病理分型肺癌组织RAR-β基因甲基化检测结果显示,鳞癌RAR-β基因甲基化检出率高于腺癌及其他,差异有统计学意义（P〈0.05）。结论肺癌有关组织或样本的RAR-β基因甲基化,可能成为各种临床类型肺癌诊断的一个有效指标。

Objective To detect methylation of RAR-β gene in tissues from non-small cell lung cancer（NSCLC） patients,and to evaluate the clinical significance.Methods The methylation of RAR-β gene in DNA from 80 NSCLC tissues and corresponding nomalignant tissues were detected with methylation-specific PCR（MSP）.Results The total frequency of RAR-β methylation was significantly higher in lung cancer tissues than that in the corresponding nomalignant tissue（57.5% vs 17.5%,P〈0.01）.But there were no significant difference in detectiveness and clinical classification.There was significant difference in clinical staging-clinical pathology type（P〈0.05）.Conclusion The detection of methylation of RAR-β gene may be helpful to clinical diagnosis for NSCLC.